The Irish Pharmaceutical Healthcare Association (IPHA) has brought attention onto what it calls the ‘Innovation Paradox’ – “the contradiction that Ireland is excellent at making new medicines but poor at making them available to patients”.
A new video and infographic explain the issue, aimed at reducing the time taken to get patients access to new medicines. IPHA quotes the European Federation of Pharmaceutical Industries and Associations (EFPIA):
“Just 45% of the new medicines licensed for prescription to patients by the EMA in 2015, 2016, 2017 and 2018 were available and reimbursed in the health services in Ireland at the end of 2019. Of the 34 European countries surveyed, 11 other countries score better than 45% for the rate of availability of new medicines in their public health systems.”